Compare Global E Online Ltd (GLBE) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Incyte Corporation — how do they compare? Global E Online Ltd trades at $40.15 (market cap $6.75B), while Incyte Corporation trades at $112.64 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 3.4× Global E Online Ltd's market cap, and Global E Online Ltd is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Incyte Corporation for 33 Days on average.
| GLBE | INCY | |
|---|---|---|
Market Cap | $6.75B | $22.85B |
Volume | 1,468,708 | 1,927,029 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $129.93 |
52-Week Low | $27.54 | $83.80 |
Typical Hold Time | 21 Days | 33 Days |
Enterprise Value | $6.24B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $40.22, up 3.23% with strong analyst support (14 buys, 1 hold). The stock shows bullish technical momentum above key support at $40, while fundamentals reveal robust revenue growth from $962M in 2025 to $1.1B projected for 2026. Recent Q2 earnings beat expectations with 44% GMV growth, though insider selling and elevated P/E of 45.65 warrant caution.
Outlook remains positive given raised 2026 guidance and 28% upside to consensus target of $48.86. Key risks include valuation sensitivity to growth execution and persistent insider selling. The appointment of a new Chief Revenue Officer signals strategic focus on scaling, but investors should monitor quarterly execution against elevated expectations.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
